Evidence map›Paper›PMID 42115740›Full record

ArticleNature microbiology2026

Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.

Alex C Stabell, Songhee Lee, Debby J Park, Christy L Lavine, Sebastian Mejia Espinosa, Viren A Baharani, Rachel Patejak, Michel C Nussenzweig, Marina Caskey, Michael S Seaman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alex C StabellWeill Cornell, Department of Infectious Diseases, New York, NY, USA.
Songhee LeeLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0009-0009-2023-051X
Debby J ParkLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-1029-7253
Christy L LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Sebastian Mejia EspinosaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Viren A BaharaniLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Rachel PatejakLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0592-8564
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1727-8693
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.ORCID http://orcid.org/0000-0002-2368-3719
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.ORCID http://orcid.org/0000-0002-7889-0766

Funding

T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
Defining the mechanisms of HIV resistance to bNAbs in humansU01AI169385 · NIAID · ROCKEFELLER UNIVERSITY · PI Marina Caskey · 2022 to 2026
$7.8M
NIAID NIH HHS T32 AI007613NIAID NIH HHS U01 AI169385U.S. Department of Health & Human Services | National Institutes of Health (NIH) 5KL2TR001865
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bnAbs) are promising agents for HIV-1 treatment and prevention. However, the genetic barriers and mutational pathways to viral resistance, which can limit therapeutic antibody utility, remain poorly defined. Here we developed a medium-to-high throughput approach to determine the mutations that confer resistance to neutralization by the bnAbs 3BNC117 and 10-1074 currently in clinical development. We performed 7,776 parallel selection experiments to identify bnAb resistance mutations in 15 primary isolates that span global HIV-1 genetic diversity. There was substantial variability among HIV-1 isolates in the identity of mutations that conferred bnAb resistance. For 12 of 15 HIV-1 isolates, single amino acid changes could increase bnAb IC

Indexed as

Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsImmune EvasionAntibodies, Monoclonal, HumanizedBroadly Neutralizing AntibodiesDrug Resistance, ViralEpitopesGenetic VariationHumansMutation3BNC117 antibodyAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV Antibodies

Identifiers

PMID42115740
PMCPMC13236584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.